Manchester Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Manchester Financial’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-583	Closed	-$15K	–	86
2021 Q1	$15K	Buy	583 +108	+23%	+$4.75K	0.01%	358
2020 Q4	$25K	Hold	475	–	–	0.02%	244
2020 Q3	$20K	Hold	475	–	–	0.02%	236
2020 Q2	$23K	Hold	475	–	–	0.02%	214
2020 Q1	$20K	Hold	475	–	–	0.01%	206
2019 Q4	$20K	Buy	+475	New	+$20.7K	0.01%	262
2019 Q3	–	Sell	-475	Closed	-$13K	–	65
2019 Q2	$13K	Buy	+475	New	+$12.1K	0.01%	296

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Manchester Financial's ACAD Position: Q2 2021 in Review

Manchester Financial sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 583 shares — an estimated $15K sold.

Manchester Financial first reported a position in ACAD in Q2 2019 and held it in 7 quarters. The position peaked at $25K in Q4 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

Manchester Financial reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Manchester Financial sold 583 Acadia Pharmaceuticals shares in Q2 2021, an estimated $15K.
Manchester Financial first reported a position in Acadia Pharmaceuticals in Q2 2019 and held it in 7 quarters.
Manchester Financial's Acadia Pharmaceuticals position peaked at $25K in Q4 2020.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Manchester Financial's 13F filing for Q2 2021, filed 21 Jul 2021.